Advances in gas chromatographic methods for the identification of biomarkers in cancer

Journal of Cancer

Volumn 3, Issue 1, 2012, Pages 404-420

  Kouremenos, Konstantinos A ^a   Johansson, Mikael ^a   Marriott, Philip J ^b  

^a UMEÅ UNIVERSITY   (Sweden)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Biomarkers; Blood; Cancer; Exhaled air; Extracellular fluid; Gas chromatography; Mass spectrometry; Metabolomics; Tissue; Urine

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 1 META TYROSINE F 18; 3' FLUOROTHYMIDINE F 18; 3,4 DIHYDROXY 6 FLUORO 1 PHENYLALANINE F 18; 4 AMINOBUTYRIC ACID; ADENOSINE TRIPHOSPHATE; AMINO ACID; BIOLOGICAL MARKER; CAMPHOR; CHOLINE C 11; DNA; FLUOROACETIC ACID F 18; FLUOROCHOLINE F 18; FLUORODEHYDROGENASE F 19; GLUTAMIC ACID; GLUTAMINE; HYPOXIA INDUCIBLE FACTOR 1; LACTATE DEHYDROGENASE; LACTIC ACID; METHIONINE C 11; MYC PROTEIN; PHOSPHOLIPID; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53; REACTIVE OXYGEN METABOLITE; THYMIDINE C 11; TRACER; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLATILE ORGANIC COMPOUND;

ANALYTIC METHOD; APOPTOSIS; BIOTRANSFORMATION; BREAST CANCER; CANCER CELL; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER THERAPY; CELL FUNCTION; CELL HYPOXIA; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; DNA SYNTHESIS; ECHOGRAPHY; ENDOSCOPY; EXPIRED AIR; FOURIER TRANSFORM MASS SPECTROMETRY; GAS CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY; LUNG CANCER; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; METABOLOMICS; NEOPLASM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ONCOGENE; ONCOLOGY; OVERALL SURVIVAL; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SOLID PHASE MICROEXTRACTION; TANDEM MASS SPECTROMETRY;

EID: 84871818709     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.4956     Document Type: Review

References (94)

1. Oliveira PA, Colaco A, Chaves HR, et al. Chemical carcinogenesis. An Acad Bras Cienc 2007; 79: 593-616.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
4. Mantovani A. Cancer: inflaming metastasis. Nature 2009; 457: 36-7.
5. Young CD, Anderson SM. Sugar and fat - that's where it's at: metabolic changes in tumors. Breast Cancer Res 2008; 10: 202.
6. Cuperlovic-Culf M. Cancer Metabolic Networks. In: Wang, E, editor. Cancer Systems Biology: CRC Press, USA; 2010.
7. Etzioni R, Urban N, Ramsey S, et al. The case for early detection. Nat Rev Cancer 2003; 3: 243-52.
8. Bhunchet E, Hatakawa H, Sakai Y, et al. Fluorescein electronic endoscopy: a novel method for detection of early stage gastric cancer not evident to routine endoscopy. GastrointestEndosc 2002; 55: 562-71.
9. Lemiere C, Peretti-Viton P, Thomas P, et al. Spreading evaluation in primitive bronchogenic carcinoma: benefit of cerebral MRI compared to CT scan. Eur J Cancer 1995; 31A: 1715.
10. Kopans DB. Lancet 1999; 354: 2096.
11. Serkova NJ, Glunde K. Metabolomics of cancer. Methods Mol Biol 2009; 520: 273-95.
12. Lindon JC, Holmes E, Bollard ME, et al. Metabolomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis. Biomarkers 2004; 9: 1-31.
13. Zuppi C, Messana I, Forni F, et al. 1H NMR spectra of normal urines: Reference ranges of the major metabolites. Clin Chim Acta 1997; 265: 85-97.
14. Gujar SK, Maheshwari S, Björkman-Burtscher I, et al. Magnetic resonance spectroscopy. J Neuroophthalmol 2005; 25: 217-26.
15. Woo HM, Kim KM, Choi MH, et al. Mass spectrometry based metabolomic approaches in urinary biomarker study of women's cancers. Clin Chim Acta 2009; 400: 63-9.
16. Phillips M, Altorki N, Austin JHM, et al. Prediction of lung cancer using volatile biomarkers in breath. Cancer Biomarkers 2007; 3: 95-109.
17. Phillips M, Altorki N, Austin JHM, et al. Detection of lung cancer using weighted digital analysis of breath biomarkers. Clin Chim Acta 2008; 393: 76-84.
18. Phillips M, Cataneo R, Cummin A, et al. Detection of lung cancer with volatile markers in the breath. Chest 2003; 123: 2115 - 23.
19. Phillips M, Cataneo RN, Condos R, et al. Volatile biomarkers of pulmonary tuberculosis in the breath. Tuberculosis 2007; 87: 44-52.
20. Phillips M, Cataneo RN, Greenberg J, et al. Effect of age on the breath methylated alkane contour, a display of apparent new markers of oxidative stress. J Lab Clin Med 2000; 136: 243-9.
21. Phillips M, Gleeson K, Hughes J, et al. Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study. Lancet 1999; 353: 1930 - 3.
22. Phillips M, Cataneo R, Ditkoff B, et al. Prediction of breast cancer using volatile biomarkers in the breath. Breast Cancer Res Treat 2006; 99: 19-21.
23. Phillips M, Boehmer JP, Cataneo RN, et al. Prediction of heart transplant rejection with a breath test for markers of oxidative stress. Am J Cardiol 2004; 94: 1593-4.
24. Phillips M, Cataneo R, Greenberg J, et al. Effect of oxygen on breath markers of oxidative stress. Eur Respir J 2003; 21: 48 - 51.
25. Fiehn O. Metabolomics - the link between genotypes and phenotypes. Potsdam: Kluwer Academic Publishers; 2002.
26. Biomarkers definitions working group. Biomarkers and surrogate end-points: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
27. Manne U, Srivastava RG, Srivastava S. Recent advances in biomarkers for cancer diagnosis and treatment. Drug Discov Today 2005; 10: 965-76.
28. Gillatt D, Reynard JM. What is the 'normal range' for prostate-specific antigen? Use of a receiver operating characteristic curve to evaluate a serum marker. Br J Urol 1995; 75: 341-6.
29. William P, Juliann C. Rational, Biologically Based Treatment of EGFR-mutant Non-small-cell Lung Cancer. Nat Rev Cancer 2010; 10: 760-74.
30. Jančík S, Drábek J, Radzioch D, et al. Clinical Relevance of KRAS in Human Cancers. J Biomed Biotechnol 2010;: 150960.
31. Horn L, Pao W. EML4-ALK: honing in on a new target in non-small-cell lung cancer. J Clin Oncol 2009; 27: 4232-5.
32. Kobayashi M, Sonobe M, Takahashi T, et al. Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer. Anti-cancer Res 2011; 31: 4619-23.
33. Sullivan PM, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001; 93: 1054-61.
34. Diamandis EP. Cancer Biomarkers: Can We Turn Recent Failures into Success? J Natl Cancer Inst 2010; 102: 1-6.
35. Simon R. Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 2005; 23: 7332-41.
36. Warburg O. The Metabolism of Tumors. London: Constable; 1930.
37. Pasteur L. Experiences et vues nouvelles sur la nature des fermentations. Comp Rend Acad Sci 1861; 52: 1260-4.
38. Cuezva JM, Krajewski M, Lopez de Heredia M, et al. The bioenergetic signature of cancer: a marker in tumor progression. Cancer Res 2002; 62: 6674-81.
39. Rossingol R, Gilkerson R, Aggeler R, et al. Energy substrate modulates mitochondrial structure and oxidative capacity in cancer cells. Cancer Res 2004; 64: 985-93.
40. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression un-covers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 2006; 9: 425 - 34.
41. Eigenbrodt E, Glossmann H. Glycolysis - one of the keys to cancer? Trends Pharmacol Sci 1980; 1: 240-5.
42. Kroemer G, Pouyssegur J. Tumor Cell Metabolism: Cancer's Achilles' Heel. Cancer Cell 2008; 13: 472-82.
43. Reinacher M, Eigenbrodt E. Immunohistological demonstration of the same type of pyruvate kinase isoenzyme (M2-PK) in tumors of chicken and rat. Virchows Arch B Cell Pathol Incl Mol Pathol 1981; 37: 79-88.
44. Mazurek S, Boschek CB, Hugo F, et al. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 2005; 15: 300 - 8.
45. Tonus C, Neupert G, Sellinger M. Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor. World J Gastroenterol 2006; 12: 7007-11.
46. Zhang H, Gao P, Fukuda R, et al. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of c-myc activity. Cancer Cell 2007; 11: 407 - 20.
47. Quintero M, Mackenzie N, Brennan PA. Hypoxia-inducible factor 1 (HIF-1) in cancer. Eur J Surg Oncol 2004; 30: 465-8.
48. Elstrom RL, Bauer DE, Buzzai M, et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 2004; 64: 3892 - 9.
49. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307 - 10.
50. Jones RG, Plas DR, Kubek S, et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 2005; 18: 283 - 93.
51. Shim H, Dolde C, Lewis BC, et al. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci USA 1997; 94: 6658 - 63.
52. Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem Sci 1999; 24: 68 - 72.
53. Chan HP, Lewis C, Thomas PS. Exhaled breath analysis: Novel approach for early detection of lung cancer. Lung Cancer 2009; 63: 164-8.
54. Miekisch W, Schubert J, Noeldge-Schomburg G. Diagnostic potential of breath analysis - focus on volatile organic compounds. Clin Chim Acta 2004; 347: 25 - 39.
55. Buszewski B, Ulanowska A, Ligor T, et al. Identification of volatile organic compounds secreted from cancer tissues and bacterial cultures. J Chromatogr B 2008; 868: 88-94.
56. Pauling L, Robinson AB, Teranishi R, et al. Quantitative Analysis of Urine Vapor and Breath by Gas-Liquid Partition Chromatography. Proc Nat Acad SciUSA 1971; 68: 2374-6.
57. Phillips M. Method for the collection and assay of volatile organic compounds in breath. Anal Biochem 1997; 247: 272 - 8.
58. Schneider JPG, Bitterlich N, Neu K, et al. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients. Anticancer Res 2003; 23: 899-906.
59. Poli D, Goldoni M, Corradi M, et al. Determination of aldehydes in exhaled breath of patients with lung cancer by means of on-fiber derivatization SPME-GC/MS. J Chromatogr B 2010; 878: 2643-51.
60. Song G, Qin T, Liu H, et al. Quantitative breath analysis of volatile organic compounds of lung cancer patients. Lung Cancer 2010; 67: 227-31.
61. Griner PF, Mayewski RJ, Mushlin AI, et al. Selection and interpretation of diagnostic tests and procedures. Principles and applications. Ann Intern Med 1981; 94 (4 pt 2): 557-92.
62. Kischkel S, Miekisch W, Sawacki A, et al. Breath biomarkers for lung cancer detection and assessment if smoking related effects. Clin Chim Acta 2010; 411: 1637-44.
63. Mieth M, Schubert JK, Groger T, et al. Automated Needle Trap Heart-Cut GC/MS and Needle Trap Comprehensive Two-Dimensional GC/TOF-MS for Breath Gas Analysis in the Clinical Environment. Anal Chem 2010; 82: 2541-51.
64. Ulanowska A, Kowalkowski T, Hrynkiewicz K, et al. Determination of volatile organic compounds in human breath for Helicobacter pylori detection by SPME-GC/MS. Biomed Chromatogr 2011; 25: 391-7.
65. Ligor T, Szeliga J, Jackowski M, et al. The analysis of healthy volunteers' exhaled breath by the use of solid-phase microextraction and GC-MS. J Breath Res 2007; 2: 046006.
66. Deng C, Zhang J, Yu X, et al. Determination of acetone in human breath by gas chromatographymass spectrometry and solid-phase microextraction with on-fiber derivatization. J Chromatogr B 2004; 810: 269-75.
67. Wu H, Xue R, Dong L, et al. Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry. Anal Chim Acta 2009; 648: 98-104.
68. Denkert C, Budczies J, Weichert W, et al. Metabolite profiling of human colon carcinoma - deregulation of TCA cycle and amino acid turnover. Mol Cancer 2008; 7: 72.
69. Perroud B, Lee J, Valkova N, et al. Pathway analysis of kidney cancer using proteomics and metabolic profiling. Molecular Cancer 2006; 5: 64.
70. Chen JL, Tang HQ, Hu JD, et al. Metabolomics of gastric cancer metastasis detected by gas chromatography and mass spectrometry. World J Gastroenterol 2010; 16: 5874-80.
71. Reichenbach SE, Tian X, Tao Q, et al. Informatics for crosssample analysis with comprehensive two-dimensional gas chromatography and high-resolution mass spectrometry (GCxGC-HRMS). Talanta 2011; 83: 1279.
72. Mal M, Koh PK, Cheah PY, et al. Metabotyping of human colorectal cancer using two-dimensional gas chromatography mass spectrometry. Anal Bioanal Chem 2012; 403: 483-93.
73. Buckendahl AC, Budczies J, Fiehn O, et al. Prognostic impact of AMP-activated protein kinase expression in ovarian carcinoma: correlation of protein expression and GC/TOF-MS-based metabolomics. Oncol Rep 2011; 25: 1005-12.
74. Lv W, Yang T. Identification of possible biomarkers for breast cancer from free fatty acid profiles determined by GC-MS and multivariate statistical analysis. Clin Biochem 2012; 45: 127-33.
75. Yang C, Richardson AD, Osterman A, et al. Profiling of central metabolism in human cancer cells by two-dimensional NMR, GC-MS analysis, and isotopomer modeling. Metabolomics 2008; 4: 13-29.
76. Kridel SJ, Axelrod F, Rozenkrantz N, et al. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res 2004; 64: 2070-5.
77. Zhang A, Sun H, Wang P, et al. Recent and potential developments of biofluid analyses in metabolomics. J Proteomics 2012; 75: 1079-88.
78. Li N, Deng C, Yin X, et al. GC/MS analysis of hexanal and heptanal in human blood by HS-SDME. Anal Biochem 2005; 342: 318-26.
79. O'Neill HJ, Gordon SM, O'Neill MH, et al. Computerized classification technique for screening for the presence of breath biomarkers in lung cancer. ClinChem 1988; 34: 1613-8.
80. Qiu Y, Cai G, Su M, et al. Serum Metabolite Profiling of Human Colorectal Cancer Using GC-TOFMS and UPLC-QTOFMS. J Proteome Res 2009; 8: 4844-50.
81. Mitra AP, Datar RH, Cote RJ. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol 2006; 24: 5552-64.
82. Pasikanti KK, Esuvaranathan K, Ho PC, et al. Noninvasive Urinary Metabonomic Diagnosis of Human Bladder Cancer. J Proteome Res 2010; 9: 2988-95.
83. Kind T, Tolstikov V, Fiehn O, et al. A comprehensive urinary metabolomic approach for identifying kidney cancer. Anal Biochem 2007; 363: 185-95.
84. Persson L, Hillered L. Chemical monitoring of neurosurgical intensive care patients using intracerebral microdialysis.. J Neurosurg 1992; 76: 72-80.
85. Persson L, Valtysson J, Enblad P, et al. Neurochemical monitoring using intracerebral microdialysis in patients with subarachnoid hemorrhage. J Neurosurg 1996; 84: 606-16.
86. Roslin M, Henriksson R, Bergstrom P, et al. Baseline levels of glucose metabolites, glutamate and glycerol in malignant glioma assessed by stereotactic microdialysis. J Neurooncol 2003; 61: 151-60.
87. Bergenheim AT, Capala J, Roslin M, et al. Distribution of BPA and metabolic assessment in glioblastoma patients during BNCT treatment: a microdialysis study. J Neurooncol 2005; 71: 287-93.
88. Tabatabaei P, Bergstrom P, Henriksson R, et al. Glucose metabolites, glutamate and glycerol in malignant glioma tumours during radiotherapy. J Neurooncol 2008; 90: 35-9.
89. Wibom C, Surowiec I, Mörén L, et al. Metabolomic patterns in glioblastoma and changes during radiotherapy: a clinical microdialysis study. J Proteome Res 2010; 9: 2909-19.
90. Mitrevski BS, Kouremenos KA, Marriott PJ. Accelerating analysis for metabolites, drugs and their metabolites in biological samples using multidimensional gas chromatography. Bioanalysis 2009; 1: 367-91.
91. Almstetter MF, Oefner PJ, Dettmer K. Comprehensive twodimensional gas chromatography in metabolomics. Anal Bioanal Chem 2012; 402: 1993-2013.
92. Kouremenos KA, Harynuk J, Winniford WL, et al. One-pot microwave derivatization of target compounds relevant to metabolomics with comprehensive two-dimensional gas chromatography. J Chromatogr B 2010; 878: 1761-70.
93. Kouremenos KA, Pitt JJ, Marriott PJ. Metabolic profiling of infant urine using comprehensive two-dimensional gas chromatography: Application to the diagnosis of organic acidurias and biomarker. J Chromatogr A 2010; 1217: 104-11.
94. Lu H, Liang Y, Dunn WB, et al. Comparative evaluation of software for deconvolution of metabolomics data based on GC-TOF-MS. Trends Anal Chem 2008; 27: 215-27.